

 Sign in or create an account

[About](#)

[Tools](#)

[Developers](#)

[Help](#)

Europe PMC plus

Search worldwide, life-sciences literature

 Search

[Advanced Search](#)

E.g. "breast cancer" HER2 Smith J

[The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms.](#)
(PMID:22766026)

 [Recent Activity](#)  [Export](#)

[Tweet](#)

[Holton KF](#), [Taren DL](#), [Thomson CA](#), [Bennett RM](#), [Jones KD](#)

Departments of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR 97239-3098, USA.
holtonk@ohsu.edu

[Clinical and Experimental Rheumatology](#) [2012, 30(6 Suppl 74):10-17]

Type: Journal Article, Randomized Controlled Trial

Abstract

OBJECTIVES: To examine the effects of a challenge with monosodium glutamate (MSG) as compared to placebo on the symptoms of fibromyalgia (FM), in participants who initially experienced >30% remission of symptoms on an excitotoxin elimination diet. **METHODS:** Fifty-seven FM patients who also had irritable bowel syndrome (IBS) were placed on a 4-week diet that excluded dietary additive excitotoxins including MSG and aspartame. Thirty-seven people completed the diet and 84% of those reported that >30% of their symptoms resolved, thus making them eligible to proceed to challenges. Subjects who improved on the diet were then randomised to a 2-week double-blind placebo-controlled crossover challenge with MSG or placebo for 3 consecutive days each week. The primary outcome measure was total symptom score. Secondary outcome measures included visual analogue pain scales (VAS for FM and IBS), an IBS Quality of Life Questionnaire (IBS QOL) and the Fibromyalgia Impact Questionnaire-Revised (FIQR). Repeated measures ANOVA was used to analyse crossover challenge results. **RESULTS:** The MSG challenge, as compared to placebo, resulted in a significant return of symptoms (total symptom score, $p < 0.02$); a worsening of fibromyalgia severity as determined by the FIQR ($p < 0.03$); decreased quality of life in regards to IBS symptoms (IBS QOL, $p < 0.05$); and a non-significant trend toward worsening FM pain based on visual analogue scale (VAS, $p < 0.07$).

About

[About Europe PMC](#)
[Funders](#)
[Joining Europe PMC](#)
[Governance](#)
[Roadmap](#)

Tools

[Tools overview](#)
[ORCID article claiming](#)
[Journal list](#)
[Grant finder](#)
[External links service](#)
[RSS feeds](#)
[SciLite annotations](#)

Developers

[Developer resources](#)
[Articles RESTful API](#)
[Grants RESTful API](#)
[SOAP web service](#)
[OAI service](#)
[Bulk downloads](#)

Help

[Help using Europe PMC](#)
[Contact us](#)

Contact us

[Helpdesk](#)
[Feedback](#)
[Twitter](#)
[Blog](#)

Europe PMC is a service of the [Europe PMC Funders' Group](#), in partnership with the [European Bioinformatics Institute](#); and in cooperation with the [National Center for Biotechnology Information](#) at the [U.S. National Library of Medicine \(NCBI/NLM\)](#). It includes content provided to the [PMC International archive](#) by participating publishers.



[Contact Us](#) | [Terms of Use](#) | [Copyright](#) | [Accessibility](#) | [Cookies](#)

